Tom Fuerst has a long-standing and distinguished track record as a senior biotechnology executive and former government official with more than two decades of experience in the research, development, and manufacturing of biological products, and strategic planning. Dr. Fuerst has served as a leader at the nexus of government, industry, and academia and brings extensive scientific expertise and knowledge of state-of-the-art technologies and practices used in the discovery and development of vaccines and biotherapeutic products. Early in his career, Dr. Fuerst was a founding scientist at MedImmune in which he helped establish its R&D programs that set the stage for the company’s future success. He later joined Sanofi Pasteur and played a key role in establishing the company’s biodefense initiative post September 11. The Department of Health and Human Services (HHS) then asked him to serve as director of vaccines and biologics, and senior science and technology advisor in the Office of the Secretary. In this capacity, he helped establish and lead a government organization, now called the Biomedical Advanced Research and Development Authority (BARDA), responsible for the development and acquisition of vaccines and immunotherapeutic products for biodefense and other emerging public health threats, including anthrax, smallpox, botulism, and pandemic flu. Dr. Fuerst also served as program director of a Defense Advanced Research Projects Agency (DARPA) initiative for the Department of Defense (DoD) to develop the concept of a dedicated, flexible capability for the advanced development and manufacturing (ADM) of biological countermeasures to address national security needs. The U.S. government now has four such ADM public-private partnerships in association with HHS and DoD. Following HHS, he transitioned back to industry to serve as executive vice president and chief scientific officer at PharmAthene, a leading biodefense company. Dr. Fuerst served as a senior fellow at the National Institutes of Health, NIAID, and holds a B.A. in biochemistry from the University of California at Berkeley, a Ph.D. in molecular genetics from Cornell University, and a MBA in science, technology, and innovation from the George Washington University. He is the recipient of several Distinguished Service Awards for leadership from HHS, serves on the Advisory Council for the College of Life Sciences at Cornell University, and participates on advisory boards in the biotechnology industry.